Lisa H. Lam

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

Gϋnter von Minckwitz, Chiun‐Sheng Huang, Max S. Mano et al. · New England Journal of Medicine · 2018 · 2.5K citations · Full text

Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non–Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers

Solange Peters, Rolf A. Stahel, Lukas Bubendorf et al. · Clinical Cancer Research · 2018 · 224 citations · Full text

Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE

Eleftherios P. Mamounas, Michael Untch, Max S. Mano et al. · Annals of Oncology · 2021 · 119 citations · Full text

First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results

Peter Schmid, Nicholas C. Turner, Carlos H. Barrios et al. · Clinical Cancer Research · 2023 · 47 citations · Full text

Efficacy, safety, and biomarker results of trastuzumab emtansine (T-DM1) in patients (pts) with previously treated HER2-overexpressing locally advanced or metastatic non-small cell lung cancer (mNSCLC).

Tom Stinchcombe, Rolf A. Stahel, Lukas Bubendorf et al. · Journal of Clinical Oncology · 2017 · 31 citations

Breast Oncology, Immunology, Pathology +16